From the TiLu Think Tank: TOPIC: Nanoparticles and Tagging CONCEPT: Dual Med Therapy

Copyright (c) 2012 TiLu Development, LLC

TiLu Think Tank

welcome to TiLu Think Tank, an irregular blog update that speculates on wild unproven ideas from science and social science on the fringe of predevelopment at the TiLu research apparatus (without exposing propietary research data, patents under development, or actual testing data that such ideas may be undergoing in our 'labs'). The content is derived from one of our meeting formats called whiteboarding. During such meetings, ideas for research topics are identified. Then going back through the list, the company mind (group think) is encouraged to think of concepts linked to that topic. There are no rules really about the concepts, they don't have to be feasible in terms of known science, may even seem inaccurate or unrelated to topics, but creative innovation is encouraged. The result is thinking outside the box in ways that may prove fruitful to invention, problem solving and further development of promising ideas.

Here is one recent topic and concept: TOPIC: NANOPARTICLES AND TAGGING; CONCEPT: DUAL MED THERAPY.

proposed: in dual med therapy, one medication marks target cells of a specific type in the body, this is called the targeting med. A second medication is then taken and that is the therapeutic agent that goes only to the targeted cells to deliver the medication. Advantage is that the targeted selectivity increases efficacy rather than a shot gun approach or side effects in other locations in the body as a consequence of treatment. An ancillary of this approach is based not only on a specific type of cell, but a specific location of the cell type--or vice versa, the targeting agent has special coded instructions that code for specific locations in the body where the bacteria (virus) is heavily concentrated. Such coding is done by nanodust particles composed of proteins that bind only to the substance that marked (or tagged) the target cells to begin with. Once the binding has occurred, the medication is released by the therapeutic agent that has just bonded with the affinity target cells. Specific locations in the body are harder to define for targeting purposes (versus types of bacteria) but some areas of the body have special kinds of fat cells or other cells unique to that location. Marking agents could be designed that bind only to those cells, but of course if we had marking agents withthat type of specificity why not engineer it so that one drug could be used that uses the same binding proteins in a therapeutic agent! One group member thought of an interesting scenario. Say you go to the dentist. You have an absessed root or infection in your gum. The dentist prescribes an engineered antibiotic that binds and delivers the medication only to the site where the absess is.